Agreement grants co-exclusive rights to Sanofi to co-commercialize Novavax’s adj. COVID-19 vaccine globally (excl. Advance Purchase Agreements existing countries, India, Japan, S. Korea); exclusive license to combine COVID-19 vaccine with flu vaccines & non-exclusive license to develop vaccines using Matrix-M adjuvant technology
Novavax to obtain $500M up front, ~$700M R&D, regulatory & launch milestones and tiered double-digit royalties on sales. Additional $200M launch & sales milestones plus mid-single digit royalties for each additional vaccine developed using technology. Sanofi will also take <5% equity investment
Sanofi to book Novavax’s COVID-19 vaccine’s sales starting in 2025, will support R&D, regulatory & commercial cost and solely develop & market the flu-COVID-19 combination vaccine. Outside collaboration, both companies are solely responsible to develop and market their products
Ref: Sanofi | Image: Sanofi
Related News:- Sanofi’s Rilzabrutinib Meets Primary Endpoint of the LUNA-3 (P-III) Study for the Treatment of Immune Thrombocytopenia (ITP)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
